(2R)-2-azaniumyl-3-(2-iodophenyl)propanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R)-2-azaniumyl-3-(2-iodophenyl)propanoate
• 化学式: C9H10INO2
• 分子量: 291.09
• InChiKey: BKXVGLPBXYBDDM-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Cyclic peptides multimers targeting alpha-4-beta-7 integrin
  申请人：Zealand Pharma A/S

  公开号：US11111273B2

  公开（公告）日：2021-09-07

  There is described herein, multimers comprising a plurality of compounds covalently linked together, the compounds independently being of formula (I).

  本文描述的多聚物由多个共价连接在一起的化合物组成，这些化合物分别独立地属于式 (I)。
• NEPRILYSIN INHIBITORS
  申请人：Theravance Biopharma R&D IP, LLC

  公开号：EP2714662B1

  公开（公告）日：2017-10-11
• CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN
  申请人：ENCYCLE THERAPEUTICS, INC.

  公开号：US20200216501A1

  公开（公告）日：2020-07-09

  There is described herein, multimers comprising a plurality of compounds covalently linked together, the compounds independently being of formula (I).
• [EN] RADIOLABELLED D-AMINO ACIDS FOR USE IN DIAGNOSIS WITH SPECT AND PET AND SYSTEMIC RADIONUCLIDE THERAPY<br/>[FR] ACIDES AMINES DE TYPE D RADIOMARQUES, UTILISES POUR LA TOMOGRAPHIE MONOPHOTONIQUE D'EMISSION ET LA TOMOGRAPHIE PAR EMISSION DE POSITONS AINSI QUE DANS LA THERAPIE ISOTOPIQUE SYSTEMIQUE
  申请人：MALLINCKRODT INC

  公开号：WO2004071505A2

  公开（公告）日：2004-08-26

  The present invention relates to D-amino acid of the general formula NH2-CHR-COOH, wherein R is a variable side chain, for use in diagnosis with SPECT and PET or in systemic radionuclide radiotherapy, wherein the D-amino acid is labelled in the side chain R, which is preferably benzyl, methyl benzyl, ethyl benzyl, 3-hydroxybenzyl or 4-hydroxybenzyl, either of which may be optionally substituted in a free ortho, meta, or para position with (CH2)n-X, wherein n is 0, 1 or 2 and X is a radioactive halogen selected from F, Cl, Br, I or a polamino polycarboxylic (PAPC) chelator. The invention further relates to pharmaceutical compositions for diagnosis or therapy of cancer.